Cerebrolysin: Benefits & Research
Part of the Cerebrolysin Complete Guide
Research Peptides
We may earn a commission if you purchase through this link, at no extra cost to you.
Stroke Recovery
Multiple randomized controlled trials demonstrate Cerebrolysin improves neurological outcomes after acute ischemic stroke. The CASTA trial (1,070 patients) showed improved NIHSS scores. Meta-analyses of stroke trials show consistent benefits for motor function recovery and daily living activities when administered within 72 hours of stroke onset.
Cognitive Enhancement
Clinical trials in vascular dementia and Alzheimer's disease show Cerebrolysin improves cognitive function scores (ADAS-cog, CGI). Effects persist for weeks after completion of a treatment course, suggesting neuroplastic changes rather than just symptomatic improvement. Response rates of 60–70% have been reported in vascular dementia trials.
Traumatic Brain Injury
Studies show Cerebrolysin improves recovery outcomes when administered in the acute phase of TBI. The neurotrophic peptides support neuronal survival, reduce secondary injury from inflammation, and promote synaptic repair — addressing multiple components of the secondary injury cascade.